A LONG-TERM FOLLOW-UP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 (AAV8)-MEDIATED GENE TRANSFER OF HUMAN ORNITHINE TRANSCARBAMYLASE (OTC) IN ADULTS WITH LATE-ONSET OTC DEFICIENCY

Registry ID

301OTC02

Source registry

HEALTH_CANADA

Status

Closed

Study type

INTERVENTIONAL

Sponsor

ULTRAGENYX PHARMACEUTICAL INC

Start date

2022-07-08

Completion date

2026-03-17

Last update

2018-07-05

Conditions

• ORNITHINE TRANSCARBAMYLASE DEFICIENCY

Related clinical trials

• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ADENOASSOCIATED VIRUS SEROTYPE 8 (AAV8)-MEDIATED GENE TRANSFER OF HUMAN ORNITHINE TRANSCARBAMYLASE (OTC) IN PATIENTS WITH LATE-ONSET OTC DEFICIENCY

View on source registry